HOME
ABOUT IAC
CONTACT
A-Z INDEX
DONATE
SHOP
SUBSCRIBE
Immunization Action Coalition
Unprotected People Stories 
General
Chickenpox (varicella)
Diphtheria
Hepatitis A
Hepatitis B
Hib
Human Papillomavirus (HPV)
Influenza
Measles
Meningococcal
Mumps
Pertussis (whooping cough)
Pneumococcal
Polio
Rabies
Rotavirus
Rubella
Shingles (zoster)
Tetanus
Yellow Fever
Stories by Disease
Stories by Number

Unprotected People Reports: Pertussis

Infant Dies after Contracting Pertussis from Adult Family Members

Click here for a fully-formatted PDF version of this report
The Immunization Action Coalition (IAC) publishes articles about people who have suffered or died from vaccine-preventable diseases and periodically devotes an IAC Express issue to such an article. This is the 72nd in our series.
In December 2004, a 29-day-old infant died from pneumonia and respiratory failure, complications of pertussis. Several weeks before the infant's birth, her mother and maternal grandmother had developed prolonged paroxysmal cough with posttussive vomiting.
According to information published in MMWR on January 28, 2005, during 1996-2004, 35.1% of pertussis patients were 6 months of age or younger (http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5403a3.htm). Infants this age are particularly vulnerable to the disease because they are too young to have received the 3-dose primary series of pertussis vaccine.
CDC describes pertussis as a highly communicable disease, transmitted from patients to close contacts by respiratory droplets. It can be severe in nonimmunized infants; healthcare workers should suspect pertussis in nonimmunized or partially immunized infants with respiratory distress.
The following case report is based on information from a medical school, hospital, and local and state public health agencies in West Virginia, as well as from NIP staff. Titled "Brief Report: Fatal Case of Pertussis in an Infant--West Virginia, 2004," it appeared in MMWR on January 28, 2005.
In December 2004, an infant aged 29 days in West Virginia died from pertussis after exposure to adult family members with probable undiagnosed pertussis. Pertussis (i.e., whooping cough) is a prolonged respiratory illness caused by the bacterium Bordetella pertussis and characterized by a violent cough, inspiratory whoop, and posttussive vomiting. The cough often lasts from several weeks to up to 3 months. However, adolescents and adults, even those previously vaccinated as children, often have disease not recognized as pertussis, leading to intrafamilial and nosocomial transmission. In the United States, children aged <6 months are at the highest risk for severe illness or death from pertussis because most infants do not complete their primary vaccination series until age 6 months. This report summarizes results of the West Virginia Department of Health and Human Resources (WVDHHR) case investigation, which underscore the critical need to prevent pertussis transmission to infants from adolescents and adults with undiagnosed disease.

On December 11, the infant was taken by her parents to a local emergency department (ED) with difficulty breathing. The infant had been coughing for approximately 5 days with increasing severity, resulting in posttussive vomiting and several choking episodes. At presentation, the infant was lethargic, and examination revealed tachycardia and mild fever (99.5 degrees F [37.5 degrees C]). Before intubation and oxygen supplementation, the infant had thick, foamy mucus coming from her mouth, appeared cyanotic, and had an O2 saturation of 70% by pulse oximetry. Seizure activity was noted during intubation. Laboratory results revealed severe leukocytosis (white blood cell count: 104,100/microliter; normal: 5,000-19,500 microliter), severe lymphocytosis (26,600/microliter; normal: 2,500-16,500/microliter), and a nasopharyngeal swab was positive for respiratory syncytial virus (RSV) by rapid immunoassay alone. A chest radiograph revealed right upper lobe and perihilar infiltrates, and an electrocardiogram indicated supraventricular tachycardia. Three hours after arrival at the ED, the infant was transferred to a pediatric intensive care unit (PICU) with diagnoses of pneumonia and respiratory failure.

On transfer to the PICU, the infant was placed on droplet precautions and contact isolation, treated for suspected sepsis, and started on azithromycin for presumed B. pertussis infection on the basis of clinical signs. The infant's ventilator course was characterized by hypoxemia (admission PaO2/FiO2 ratio: 172) and increasing hypercarbia. Sequential cardiac ultrasounds demonstrated increasing pulmonary hypertension (right ventricular pressure: 2/3 systemic). Nineteen hours after admission, oxygenation worsened precipitously (PaO2/FiO2 ratio: 52-60) and failed to improve with nitric oxide administration or high-frequency ventilation. A double-volume exchange transfusion was performed, but the infant failed to improve and died approximately 30 hours after admission to the PICU.

A specimen obtained from the infant's nasopharynx after admission to the PICU was reported at the time of the infant's death to be positive for B. pertussis DNA and negative for B. parapertussis DNA by polymerase chain reaction (PCR); however, no specimen was submitted for culture. Results were negative by both rapid immunoassay and culture for RSV, influenza A and B, and parainfluenza viruses 1, 2, and 3, and negative by culture for adenovirus. The diagnosis of confirmed pertussis was based on history, clinical findings, and a positive PCR test. The infant might have had a coinfection with RSV based on the positive RSV rapid immunoassay at the ED; this result was not confirmed by a repeat RSV rapid immunoassay or by culture at the PICU.

The infant was born at 36 weeks' gestation (birth weight: 2,665 g) by normal, uncomplicated, vaginal delivery. The infant's mother, aged 20 years, had a prolonged paroxysmal cough with posttussive vomiting and whoop that began approximately 3 weeks before the infant's delivery. The cough was still present at the time of the infant's death. The mother received guaifenesin/dextromethorphan cough syrup after delivery. The infant's maternal grandmother, aged 58 years, had a prolonged paroxysmal cough illness (onset date: approximately 2 weeks before the infant's mother's illness) with posttussive vomiting; she had received azithromycin after a diagnosis of sinusitis. Two weeks before the infant's illness, the infant's father, aged 22 years, had onset of a paroxysmal cough illness of >3 weeks' duration.

A day after the infant's death, a case investigation identified four additional close contacts (two cousins, a paternal grandmother, and a great-grandmother) of the infant with cough illness (duration: 3-8 days) at the time of the infant's death. The birth hospital and the ED had no droplet precautions in place while the infant and the infant's symptomatic family members were in the facilities; 30 birth hospital and 11 ED employees were identified as potential contacts. The local health department and the ED provided erythromycin to 24 recent (i.e., during the preceding 3 weeks) contacts of the infant and symptomatic family members. Of nine nasopharyngeal swabs submitted for culture, all were negative for pertussis (all household members swabbed had been symptomatic for >3 weeks); no PCR testing for pertussis was performed. Pertussis alerts were issued to the public, healthcare providers, schools, and a large retail store where the infant's father worked.

This case underscores the need to protect infants from pertussis transmission. The healthcare community can limit the spread of pertussis by (1) educating caretakers and the public about preventing exposure of infants to any person with a cough illness, (2) educating healthcare providers to consider pertussis in adolescents and adults with a cough illness and to ask these patients to wear a mask or isolate themselves from other patients, and (3) encouraging confirmation of pertussis by culture of nasopharyngeal secretions. Healthcare providers must be encouraged to observe droplet precautions while attending to patients with respiratory illnesses. No U.S.-licensed pertussis vaccine for persons aged >=7 years is available; however, in 2004, two pharmaceutical companies submitted biologics license applications to the Food and Drug Administration for two tetanus toxoid and reduced diphtheria toxoid and acellular pertussis vaccine adsorbed (Tdap) products, one for persons aged 10-18 years and the other for persons aged 11-64 years.
2/1/05 • REPORT #72
Disclaimer: The Immunization Action Coalition (IAC) publishes Unprotected People Reports for the purpose of making them available for our readers' review. We have not verified the content of this report.
 
- Guide to immunize.org -
A-Z INDEX
ABOUT IAC
IAC in the News
Staff
IAC History through Film
ACIP
RECOMMENDATIONS
ADOLESCENT VACCINATION
ADULT VACCINATION
ADULT VACCINATION GUIDE
ASK THE EXPERTS
Administering Vaccines
COVID-19 & Routine Vac
Hepatitis B
MMR
Storage and Handling
>> view all
BECKY PAYNE AWARD
BILLING & CODING
BIRTH DOSE GUIDEBOOK
CALENDAR OF EVENTS
CDC INFORMATION
CDC SCHEDULES
CLINIC TOOLS
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Screening for Contraindications
Vaccination and COVID-19
Vaccine Recommendations
Vaccine Storage & Handling
>> view all
COALITIONS FOR
IMMUNIZATION
CONTRIBUTE TO IAC
COVID-19 RELATED
Ask the Experts: COVID-19
   & Routine Vac
Clinic Tools: Vaccination and
   COVID-19
Repository of Resources
DEAR COLLEAGUE LETTERS
16-year-old Visit
HPV
MenACWY Dose #2
DONATE TO IAC
EDUCATIONAL MATERIALS
EMAIL NEWS SERVICES
E-NEWSLETTER: IAC EXPRESS
EXEMPTIONS
FAQs
FAVORITES
FDA PACKAGE INSERTS
FILMS ABOUT IAC
GIVE BIRTH TO THE
END OF HEP B
HANDOUTS FOR
PATIENTS & STAFF
View All Materials
Administering Vaccines
Adolescent Vaccination
Adult Vaccination
Contraindications / Precautions
Documenting Vaccination
Healthcare Personnel
Managing Vaccine Reactions
Parent Handouts
Pregnancy and Vaccines
Q&As: Diseases and Vaccines
Q&As: Easy-to-Read
Schedules for Patients
Screening Checklists
Standing Orders Templates
Storage & Handling
Strategies & Policies
Temperature Logs
Top Handouts
Vaccine Confidence
Vaccine Recommendations
>> view all
HEP B BIRTH DOSE
HONOR ROLLS
Hep B Birth Dose
Mandatory Flu Vaccination for HCP
MenB Vaccination for Colleges
IAC EXPRESS
Subscribe to IAC Express
IMAGE LIBRARY
LAWS AND MANDATES
MANUFACTURERS
MASS VACCINATION
RESOURCES
NATIONAL ADULT &
INFLUENZA
IMMUNIZATION SUMMIT
NEWS & INFORMATION
NEWSLETTER SIGN UP
OFFICIAL RELEASES
ACIP
CDC
FDA
PACKAGE INSERTS
PARTNERS
PHARMACISTS
PHOTOS
POWERPOINT SLIDE SETS
PREGNANCY AND
VACCINES
PRESS ROOM
PROTECT NEWBORNS
FROM HEP B
PUBLICATIONS
IAC Express
Vaccinating Adults:
   A Step-by-Step Guide
Hepatitis B What Hospitals
   Need to Do to
   Protect Newborns
Needle Tips Archive
Vaccinate Adults Archive
Vaccinate Women Archive
REGISTRIES
SCHOOL VACCINATION REQUIREMENTS
SHOP IAC
DVD Immunization Techniques
Laminated Schedules
Patient Record Cards
Flu Vaccine Buttons and Stickers
"Vaccines Save Lives" Pins
SITE MAP
SLIDE SETS
STANDING ORDERS
STATE INFORMATION
Immunization Websites
Laws and Mandates for School Entry
Immunization Program Managers
SUBSCRIBE TO IAC EXPRESS
SUPPORT IAC
TALKING ABOUT VACCINES
Adjuvants & Ingredients
Autism
Importance of Vaccination
MMR Vaccine
Religious Concerns
Vaccine Safety
>> view all
TECHNICALLY SPEAKING
TRANSLATIONS
IAC Handouts
VISs
TRAVEL (INTERNATIONAL)
UNPROTECTED PEOPLE
STORIES
Chickenpox
Hepatitis B
Measles
Whooping Cough
>> view all
VACCINATING ADULTS:
A STEP-BY-STEP GUIDE
VACCINE INFORMATION
STATEMENTS
Translations
VACCINE
MANUFACTURERS
VACCINE POLICY &
LICENSURE
ACIP
FDA
WHO
VACCINE SAFETY
VACCINE TIMELINE
VACCINES
Hepatitis B
HPV (Human papillomavirus)
Influenza
Pertussis
Varicella
>> view all
VIDEO OF THE WEEK
VIDEO LIBRARY
VISs
Translations
WHAT'S NEW OR UPDATED AT IAC
Handouts
VISs and Translations
Web Pages
 
Immunization Action Coalition  •  2550 University Avenue West  •  Suite 415 North  •  Saint Paul, Minnesota  •  55114
tel 651-647-9009  •  fax 651-647-9131
 
 
 
This website is supported in part by a cooperative agreement from the National Center for Immunization and Respiratory Diseases (Grant No. 6NH23IP22550) at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The website content is the sole responsibility of IAC and does not necessarily represent the official views of CDC.